NASDAQ:GTBP

GT Biopharma Q3 2026 Earnings Results & Report

GT Biopharma logo
$2.96 -0.22 (-6.92%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.75 -0.21 (-7.06%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GT Biopharma beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$1.98 versus the -$2.50 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

GT Biopharma EPS Results

Actual EPS
-$1.98
Consensus EPS
-$2.50
Beat/Miss
Beat by +$0.52
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

GT Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GT Biopharma Q3 2026 Earnings FAQ

GT Biopharma (NASDAQ:GTBP) reported earnings of -$1.98 per share for Q3 2026, beating the consensus estimate of -$2.50. The report was announced on Monday, November 16, 2026.

GT Biopharma Earnings Headlines

GT Biopharma Reports Third Quarter 2026 Financial Results
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
GT Biopharma Regains Nasdaq Minimum Bid Compliance
See More GT Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GT Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GT Biopharma and other key companies, straight to your email.

About GT Biopharma

GT Biopharma (NASDAQ:GTBP) (NASDAQ: GTBP) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research centers on its TriKE platform, which is designed to direct natural killer (NK) cells toward cancer cells and support their activity using an immune-stimulating signal.

The company’s pipeline includes GTB-3650, a candidate designed to target CD33-expressing blood cancers such as acute myeloid leukemia, and GTB-5550, a candidate targeting B7-H3, a protein found on various solid tumors. These candidates remain in development; GT Biopharma does not have a marketed cancer therapy.

View GT Biopharma Profile